Who We Are

The Ruth Group (TRG) team is distinguished by its deep experience in investor relations and public relations, along with the breadth and depth of its healthcare expertise.

Our services include comprehensive investor relations and public relations counsel across the key sectors in healthcare, including medical technology, tools/diagnostics, life sciences (biotechnology, specialty pharma/pharmaceuticals), and healthcare services/HCIT.

Our structure drives our flexibility, creative thinking and rapid responsiveness, with senior leadership closely involved with every client. We are based in New York City, placing our team at the center of the world’s capital and media markets.

TRG Team:

Carol Ruth
Founder and CEO

As a leader in the investor relations and public relations profession, Carol has built a reputation for providing clients with strategic communications advice and counsel across a wide range of issues. She has a strong track record working with a wide range of healthcare companies in all sub-sectors and stages of development. In 2010, she was recognized by IR Magazine as the recipient of the “Lifetime Achievement in Investor Relations” Award.

Carol prides herself on direct involvement with all clients and the counsel she offers her staff on client issues. She has a demonstrated ability to develop talent and professionals with exceptional dedication to the field.

Carol founded The Ruth Group in 1999 to focus on providing healthcare clients with strategic communications counsel and a high level of client service. Prior to founding The Ruth Group, she was chairman and chief executive officer of Edelman Financial Worldwide, with responsibility for the firm’s global investor relations and financial public relations practices. Before joining Edelman in 1997, Carol was founder, president and chief executive officer of Dewe Rogerson, founding and building the firm into a leading cross-border agency strategic communications agency.

Prior to Dewe Rogerson, Carol was senior vice president of Hill and Knowlton’s Financial Division for 18 years. She is a senior member of the U.S. investor relations trade group having served as national chairman and a member of the group’s ethics committee.  One of the pioneers in investor relations, Carol has been instrumental in setting standards for investor communications.  She has lectured domestically and internationally on both investor and public relations best practices.

Nick Laudico
Executive Vice President

Nick Laudico has led The Ruth Group’s medical technology and tools/diagnostics team since 2003 and provides investor relations counsel on messaging and program design and execution.  He has planned and executed numerous investor relations programs for pre-IPO and established public companies in the healthcare sector. Nick is experienced in communications counsel for a wide range of transactions, including IPOs, follow-on offerings, debt offerings, and mergers and acquisitions. He has a special focus on counseling clients through the transition from private to public ownership, managing Wall Street expectations/financial guidance counsel, and handling positive/negative earnings surprises. Nick also has strong relationships with leading healthcare institutional investors and sell-side analysts and has facilitated client introductions to several top-tier firms.

Prior to joining The Ruth Group, Nick was at Brainerd Communicators where he focused on strategic corporate communications campaigns for Fortune 500 companies such as Comcast and Liberty Media, as well as motion picture corporations Pixar and Viacom.  Prior to that, he was at Travers Collins and Company, a full-service marketing communications agency. He received a bachelor of arts from the University at Buffalo.

Zack Kubow
Senior Vice President

Zack Kubow joined The Ruth Group in 2004. He has specialized experience in development and execution of strategic investor relations and public relations programs for companies in the medical device and tools/diagnostics and life sciences sectors.  Zack develops and implements IR client programs that reflect each client’s capital needs, investment criteria and business plan.

Zack provides TRG clients with impeccable day to day IR strategy, investor targeting, and investor message development.

Zack earned his BS in Biology with focus on Human Health from University of California, Berkeley.

Lee Roth
Senior Vice President

Lee Roth specializes in investor relations for public and pre-IPO companies. He has nearly 15 years of experience developing and executing strategic communications programs for companies across a wide range of industries, valuations and regions.

He joined TRG from The Piacente Group, a boutique investor relations agency, where he spent four years as a Vice President leading the day-to-day program execution for approximately 15 domestic and international companies, providing clients high-level strategic and tactical support for transactions including IPOs and secondary offerings, privatizations and M&A, as well as crisis situations.

Prior to joining the Piacente Group, Lee was director of investor and analyst relations at Solid Ground USA, the U.S. subsidiary of a European PR and marketing firm. Previously, he was managing director and head of the investor relations practice at KCSA Strategic Communications, a New York-based independent public and investor relations agency, where he led the firm’s international and technology groups.

He holds a Bachelor’s Degree in English, with a concentration in Journalism and Professional Writing from The College of New Jersey.

Robert E. Flamm, Ph.D., MBA
Senior Vice President

Robert Flamm joined TRG in 2016. He develops and executes strategic investor relations programs for public and pre-IPO healthcare companies. He has worked with companies across the healthcare industry including biotechnology, pharmaceuticals, medical technology and diagnostics.

Robert's diverse background prior to joining TRG provides a unique perspective that can add additional value to clients. Prior to joining TRG, Robert spent eight years at Russo Partners developing and directing investor relations and corporate communications programs for emerging life science companies. Before becoming an investor relations consultant, Robert spent over 13 years on Wall Street as a sell-side and buy-side analyst covering all sectors of healthcare across a wide range of market capitalizations. This experience as a "consumer of investor relations" has enabled him to communicate that perspective to clients, which can then be integrated into company strategy and messaging. Prior to becoming an analyst, Robert trained as a neuroscientist through the post-doctoral level for 10 years. This background enables him to rapidly understand a client's products and target markets and contributes an additional level of expertise to their communication programs.

Robert holds a B.S. in Zoology from the University of Massachusetts in Amherst, a Ph.D. in Neurobiology and Behavior from Cornell University and an M.B.A. from Columbia University Business School.

Tram Bui
Vice President

Tram Bui specializes in the development and execution of strategic investor relations programs for public and private companies in the life sciences sector, leveraging her deep knowledge of the healthcare sector and strong buy and sell side connections.

Prior to joining The Ruth Group, she served as a Director at KCSA Strategic Communications, an independent public and investor relations agency, focused on developing successful investor communications platforms and capital raises for a broad base of public healthcare companies. Tram spent 9 years on Wall Street as a buy-side healthcare analyst on a small cap fund at Lazard Asset Management as well as an institutional equity sales associate at CJS Securities. She was also an entrepreneur, having co-founded and led the operations of a Brazilian import company from 2009 to 2014.

Tram received her Bachelor of Science in Marketing from the University of New Orleans.

Sharon Choe
Vice President

Sharon Choe specializes in development and execution of strategic investor relations programs for public and pre-IPO companies in the life sciences sector. She has 23 years of experience in life sciences, having worked in buy-side research.

Sharon joined TRG from LifeSci Advisors, a healthcare focused investor relations and equity research firm. Prior to joining LifeSci Advisors, she was the biotech analyst at BAM Capital LLC  where she was responsible for generating long/short portfolio positions and hedging strategies. Sharon was also the healthcare analyst at Credit Suisse Asset Management, where she co-managed the Global Healthcare fund. Prior to that, she worked at UBS Asset Management as the large and midcap Healthcare analyst.

Sharon earned her BS in Pharmacy from Northeastern University in Boston, MA

Kirsten Thomas
Vice President

Kirsten Thomas specializes in public and media relations for high-science biotech, pharmaceutical and medical device companies. She has deep experience with companies dedicated to oncology, nerve repair, regenerative medicine and spinal system technology. Kirsten leads the day-to-day public relations programs across all her clients, with a strong emphasis on developing targeted media strategy and maximizing client coverage.

Prior to joining the TRG team, Kirsten supported public relations for a number of biotech and pharmaceutical companies at the healthcare agency GCI Health. She focused primarily in the oncology and multiple sclerosis spaces, with experience in aesthetic treatments, infectious diseases and dermatology. Kirsten functioned in a number of capacities, including leading day-to-day activities, program planning and media strategy across accounts, with particular strength in media campaign execution, news and feature writing, and event planning.  

Kirsten graduated magna cum laude from Syracuse University with a dual B.A. in biology and public relations.

Chris Nardo
Senior Marketing Analyst
Janhavi Mohite
Senior Account Executive
Joanna Zimmerman
Senior Account Executive
Alex Lobo
Senior Account Executive
Augustus Jenkins
Senior Account Executive
Brian Johnston
Senior Analyst
Emma Poalillo
Analyst